DGAP-Media / 2019-10-01 / 14:48
*curasan launches product for the treatment of the spinal facet syndrome*
- *curasan receives CE clearance for Spinevisc(R) Hyaluronic Acid for the
treatment of spinal facet joint arthrosis*
*- Extended reach to new target groups in the Spine, Neuroradiology and
Interventional Pain Therapy market*
Kleinostheim, October 1st, 2019 - curasan AG, Germany, a leading specialist
for medical products in the field of orthobiologics and interventional pain
management, launches Spinevisc(R), a biomimetic hyaluronic acid with a
medium molecular weight similar to the body's own synovial fluids, dedicated
for the treatment of the widespread facet syndrome (facet joint arthrosis).
"The launch of Spinevisc(R) sets another milestone in the history of
curasan", states Torben Sorensen, new CEO of curasan. "Despite the currently
challenging market and regulatory environment, our interdisciplinary team of
Marketing, Medical Affairs and Regulatory specialists have managed to bring
a product to market that is dedicated to treat the painful symptoms of the
widespread facet syndrome."
"Spinevisc(R) will allow curasan to extend its reach and to address new
target groups such as specialized Neuroradiologists and Interventional Pain
Therapists, as well as Spine surgeons, thus allowing the company in entering
entirely new distribution channels and an untouched market segment", states
Gregor Siebert, Director of Marketing and Sales.
"With over a decade experience in arthrosis management with curasan's
proprietary hyaluronic acid formula, it was a logical step for us to further
focus on how we could possibly address the needs of a minimally-invasive,
yet safe and easy-to-apply solution in treating back pain caused by the
facet syndrome", adds Florian Früh, Head of Product Management.
curasan will launch Spinevisc(R) during the German Orthopedic and
Traumatology Congress (DKOU), to be held between October 22-25 in Berlin,
Germany, followed by the Spine Interventional Neuroradiology Symposium of
the European Society of Neuroradiology (ESNR), to be held from October 25-27
in Malta.
*Contact curasan AG: *
Andrea Weidner
IR & Corporate Communications
pr@curasan.com
*Contact for product related requests:*
Florian Früh
Head of Product Management
florian.frueh@curasan.com
*About curasan AG:*
curasan develops, manufactures and markets biomaterials and medical devices
in the field of bone and tissue regeneration, wound healing and
osteoarthritis therapy. As a pioneer and global technology leader in the
growing field of regenerative medicine, curasan is specialized primarily on
biomimetic bone grafting materials for dental, oral/maxillofacial,
orthopedic and spinal applications, i.e. materials mimicking biological
structures. Numerous patents and a broad record of scientific publications
demonstrate the clinical success of the products and the highly innovative
strength of curasan.
End of Media Release
Issuer: curasan AG
Key word(s): Health
2019-10-01 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: curasan AG
Lindigstraße 4
63801 Kleinostheim
Germany
Phone: 06027/40 900 0
Fax: 06027/40 900 29
E-mail: info@curasan.de
Internet: www.curasan.de
ISIN: DE000A2YPGM4
WKN: A2YPGM
Listed: Regulated Market in Frankfurt (General Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
EQS News ID: 883551
End of News DGAP Media
883551 2019-10-01
(END) Dow Jones Newswires
October 01, 2019 08:48 ET (12:48 GMT)
